arbiter
JournalsPricingAccount

Cost-effectiveness, public health impact, and budget impact of receipt of Pfizer-BioNTech COVID-19 vaccine, LP.8.1-adapted, 2025/2026 formula among adults aged 18 years and older at high risk for severe outcomes from COVID-19 in the United States

Alon Yehoshua et al.

Journal of Medical Economics2026https://doi.org/10.1080/13696998.2026.2644761article
ABDC C
Weight
0.50

What the paper says

Vaccinating adults at high risk of severe COVID-19 with the LP.8.1-adapted Pfizer BioNTech COVID-19 Vaccine is projected to be a cost-saving measure from the societal perspective that could reduce the public health and economic burden of COVID-19.

Open paper page →

Cite this paper

https://doi.org/https://doi.org/10.1080/13696998.2026.2644761

Or copy a formatted citation

@article{alon2026,
  title        = {{Cost-effectiveness, public health impact, and budget impact of receipt of Pfizer-BioNTech COVID-19 vaccine, LP.8.1-adapted, 2025/2026 formula among adults aged 18 years and older at high risk for severe outcomes from COVID-19 in the United States}},
  author       = {Alon Yehoshua et al.},
  journal      = {Journal of Medical Economics},
  year         = {2026},
  doi          = {https://doi.org/https://doi.org/10.1080/13696998.2026.2644761},
}

Paste directly into BibTeX, Zotero, or your reference manager.

Flag this paper

Cost-effectiveness, public health impact, and budget impact of receipt of Pfizer-BioNTech COVID-19 vaccine, LP.8.1-adapted, 2025/2026 formula among adults aged 18 years and older at high risk for severe outcomes from COVID-19 in the United States

Flags are reviewed by the Arbiter methodology team within 5 business days.

Evidence weight

0.50

Balanced mode · F 0.40 / M 0.15 / V 0.05 / R 0.40

F · citation impact0.50 × 0.4 = 0.20
M · momentum0.50 × 0.15 = 0.07
V · venue signal0.50 × 0.05 = 0.03
R · text relevance †0.50 × 0.4 = 0.20

† Text relevance is estimated at 0.50 on the detail page — for your query’s actual relevance score, open this paper from a search result.